GSK to close Stevenage R&D site, shift 1,000+ scientists to Cambridge

GSK will shut its Stevenage R&D site by 2029 and move over 1,000 scientists to a new Cambridge facility, part of a programme to save £1.9bn yearly at a £2.4bn implementation cost. Global redundancy figures were not disclosed. The move concentrates UK pharma R&D around Cambridge, where AstraZeneca pledged £200m in April 2026.